GSK (GSK, Financial) has submitted an application to the European Medicines Agency (EMA) to extend the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, to adults aged 18 years and older. Initially, Arexvy was the first vaccine approved in the European Economic Area for preventing lower respiratory tract disease caused by RSV in individuals 60 years and older, as well as those aged 50-59 at higher risk. The EMA is expected to make a decision on this proposal in the first half of 2026. In addition to Europe, GSK is actively pursuing regulatory approval for expanded indications of its RSV vaccine in markets such as the US and Japan.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.